Hualan Biological Vaccine Inc. (SHE:301207)
China flag China · Delayed Price · Currency is CNY
14.05
-0.15 (-1.06%)
Nov 17, 2026, 3:04 PM CST

Hualan Biological Vaccine Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash & Equivalents
567.22352.94623.04640.98600.04131.56
Short-Term Investments
1,165458.641,145373.46130-
Trading Asset Securities
1,5261,9731,4581,5991,419825.82
Cash & Short-Term Investments
3,2592,7853,2272,6132,149957.39
Cash Growth
5.95%-13.69%23.48%21.57%124.50%10.65%
Accounts Receivable
911.591,3491,4381,9901,7961,439
Other Receivables
0.610.010.411.310.412.15
Receivables
912.21,3491,4382,4121,8561,441
Inventory
372.23179.2208.84173.47167.16107.41
Other Current Assets
490.8869.81103.1328.1820.2223.31
Total Current Assets
5,0344,3834,9775,2274,1932,529
Property, Plant & Equipment
844.96943.711,0711,1761,2871,351
Long-Term Investments
-1,2761,2041,2961,310356.3
Other Intangible Assets
20.3620.0920.8820.1320.7821.43
Long-Term Deferred Tax Assets
202.94189.06212.73217.97208.56182.9
Long-Term Deferred Charges
27.9327.9227.7927.9428.6933.36
Other Long-Term Assets
140.184.8211.0530.6127.9848.93
Total Assets
6,2706,8447,5237,9957,0764,523

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Accounts Payable
89.0560.9881.78116.76125.67185.5
Accrued Expenses
-909.3903.531,1551,050929.48
Short-Term Debt
--300.18300.18300.18500.44
Current Portion of Leases
-----1.03
Current Income Taxes Payable
21.25--50.819.2415.99
Current Unearned Revenue
17.993.68.742.672.681.54
Other Current Liabilities
957.88143.14169.960.6349.1338.19
Total Current Liabilities
1,0861,1171,4641,6861,5371,672
Long-Term Leases
-----0.81
Long-Term Unearned Revenue
19.7822.9527.1931.4235.6639.89
Long-Term Deferred Tax Liabilities
--18.815.226.412.5
Total Liabilities
1,1061,1401,5101,7321,5791,715

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Common Stock
601.03601.03601.03600.02400.01360
Additional Paid-In Capital
2,9102,9102,9262,9153,089879.79
Retained Earnings
1,7602,3002,5932,7482,0081,568
Treasury Stock
-106.79-106.79-106.79---
Shareholders' Equity
5,1645,7046,0136,2635,4972,808
Total Liabilities & Equity
6,2706,8447,5237,9957,0764,523

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Total Debt
--300.18300.18300.18502.27
Net Cash (Debt)
3,2592,7852,9262,3131,849455.12
Net Cash Growth
5.95%-4.84%26.53%25.07%306.31%-31.59%
Net Cash Per Share
5.494.684.893.843.130.84
Filing Date Shares Outstanding
595595595600.02600.02600.02
Total Common Shares Outstanding
595595595600.02600.02540
Working Capital
3,9483,2663,5123,5412,656857.07
Book Value Per Share
8.689.5910.1110.449.165.20
Tangible Book Value
5,1445,6845,9926,2435,4762,787
Tangible Book Value Per Share
8.659.5510.0710.409.135.16
Buildings
-376.55376.55376.55376.19375.5
Machinery
-1,5031,4961,4721,4501,388
Construction In Progress
-10.276.723.233.26-